Sebastian von der Emde

Cardiology Resident at Heart Center Leipzig | PhD Student at Medical University of Innsbruck | #whyCMR

[Davide Capodanno @DFCapodanno]

OPTIMAL suggests that using IVUS in unprotected left main PCI may cost you 22 minutes with no clinical benefit. One might think it’s an outlier. Yet, the same day, IVUS-CHIP reports no advantage of IVUS over angiography in complex high-risk PCI. Either we have been fundamentally misinterpreting the evidence so far, or we urgently need to reconcile these data. #ACC26
https://t.co/eoJzCtVy8h
https://t.co/6kYUhV1Sbm

[Sebastian J Reinstadler @ReinstadlerSJ]

Our #whyCMR paper in @JACCJournals shows that reperfused STEMI with intramyocardial hemorrhage (IMH) have a much higher risk of MACE than STEMI with MVO but not IMH. IMH=key culprit driving MACE post-MI. @lechner_i @imed_tweets https://t.co/emcs1mvGed

[NEJM @NEJM]

Presented today at #ACC24:

In the DanGer Shock trial involving patients with STEMI and cardiogenic shock, mortality at 6 months was lower with mechanical circulatory support with a microaxial flow pump than with standard care alone. Full trial results: https://t.co/3625asvzu8

[Sebastian J Reinstadler @ReinstadlerSJ]

Our most recent publication on the relation of plasma neuropeptide-Y with infarct severity after #STEMI
Check out here: https://t.co/zoEUt421lp
@CT_Tiller @HolzknechtM
@imed_tweets @lechner_i #whyCMR

[Holger Thiele @thiele_holger]

Comprehensive review on VA-ECMO
@DGK_AG3 @TRassafMD

[Sebastian von der Emde @vonderEmdeS]

great meeting

@LuisEichelmann @DocDerda @LucasBacmeister @larawald @BenediktKoell @sebFeickert

[Young DGK @YoungDgk]

Tolle Atmosphäre bei der ersten #AutumnSchool im @UHZ_UNIFreiburg am Standort Bad Krozingen. Tolle interaktive Vorträge und viele interessierte Teilnehmer
@Hannah_Billig_ @AnnaHohneck @_Ramona_Schmitt @LuisEichelmann @andreaskardio @Mukaram_Rana89 @LucasBacmeister @Kardiophil

[John Mandrola, MD @drjohnm]

This morning on @Sensible__Med the Study of the Week is the ECLS-SHOCK trial.

Gosh does it teach us important lessons. Not only about cardiogenic shock but the importance of randomization

https://t.co/mAR5sN1sBt

Congrats--again--to @thiele_holger et al
#cardiotwitter

[Sebastian von der Emde @vonderEmdeS]

🙏🏼

[Sebastian von der Emde @vonderEmdeS]

fresh data on #whyCMR guidance in TAVI

[Circulation @CircAHA]

#JustPublished: Cardiac Magnetic Resonance Imaging Versus Computed Tomography to Guide Transcatheter Aortic Valve Replacement (TAVR-CMR) #CircESC23 https://t.co/Ee1FpCRqpG

[NEJM @NEJM]

Presented at #ESCCongress:

In this randomized trial, extracorporeal life support did not improve 30-day survival as compared with usual care in patients with acute myocardial infarction complicated by cardiogenic shock.

Full ECLS-SHOCK trial results: https://t.co/gsxcdgQpg9

[JACC Journals @JACCJournals]

Insights from #FLASH registry: >1/3 of intermediate risk #PE patients were in normotensive shock with ⬇️ CI. #Thrombectomy improved hemodynamic & functional outcomes at 30 days. https://t.co/FrEDMuPPiK

#JACCINT #cvAMI #CardioTwitter @SripalBangalore @jameshorowitzmd

[EHJ Editor-in-Chief @ehj_ed]

Lipoprotein(a) is linked to atherothrombosis and aortic valve stenosis independent of C-reactive protein. Read more in EHJ!
https://t.co/D3JpC6Z8ud
#atherosclerosis #aorticstenosis #inflammation #Creactiveprotein #EHJ #cardiotwitter @ESC_Journals @escardio

[Holger Thiele @thiele_holger]

Thank you!
More students always welcome!

[Sam Ghali, M.D. @EM_RESUS]

Here’s a video I made breaking down my perspective on what happened to Damar Hamlin on January 2nd, 2023. He has now officially come out and confirmed the diagnosis. Retweet to spread awareness.

[European Society of Cardiology @escardio]

#eBRAVE_AF trial: #AFib screening using conventional smartphones more than doubles the detection and treatment rate in older people compared to routine screening.

#ESCCongress

[European Society of Cardiology @escardio]

#REVIVED trial: Percutaneous coronary intervention does not reduce all-cause mortality or #heartfailure hospitalisation in patients with severe left ventricular dysfunction and extensive #coronary artery disease.

#ESCCongress

[JACC Journals @JACCJournals]

A 32 y/o ♂️ w/ PMH of unprovoked PE and #STEMI ➡️ heterozygous prothrombin mutation (G20210A) ➡️ on #DOAC ➡️ presented w/ exertional dyspnea ➡️ #whyCMR: 2 LV thrombi ➡️ surgical thrombectomy + vitamin K antagonist. https://t.co/bYw3zowElM

#JACCCaseReports #CardioTwitter